Both for type 2 diabetes. Mounjaro (tirzepatide) demonstrates superior glycemic control and ~47% greater weight loss in the SURPASS-2 head-to-head trial vs Ozempic (semaglutide).
Both for type 2 diabetes. Mounjaro (tirzepatide) demonstrates superior glycemic control and ~47% greater weight loss in the SURPASS-2 head-to-head trial vs Ozempic (semaglutide).
For the full clinical evidence, see clinical research and main comparison page.
Compounded semaglutide + tirzepatide · MD/DO oversight
*12-month plan · flat rate · all titration doses
Or call (949) 818-8000